Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804868 | 1.00 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL1804866 | 1.00 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL6099960 | 1.00 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL15345991 | 0.96 | SPPL2A (0.54) | SPPL2A | |
| SCHEMBL15345993 | 0.96 | SPPL2A (0.54) | SPPL2A | |
| SCHEMBL13345939 | 0.93 | SPPL2A (0.59) | SPPL2A | |
| SCHEMBL7526248 | 0.92 | SPPL2A (0.51) | SPPL2A | |
| SCHEMBL13567521 | 0.92 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL13538009 | 0.92 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL11988982 | 0.91 | SPPL2A (0.57) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9499558-B2 | Compounds and methods for treating HIV | PURDUE RESEARCH FOUNDATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-9309213-B2 | C-3 substituted bicyclooctane based HIV protease inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-13 | — | — | US | disclosed |
| US-20140148508-A1 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | PURDUE RESEARCH FOUNDATION | 2013-10-31 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-8501961-B2 | HIV protease inhibitors and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2216334-A1 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010006050-A1 | HIV PROTEASE INHIBITORS AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1709037-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LAB (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1678158-B1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2008-03-26 | — | — | EP | disclosed |
| EP-1673364-B1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2007-08-22 | — | — | EP | disclosed |
| EP-1678158-A1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP Assets B.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| EP-1673364-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP Assets B.V. (NL) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040149-A1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS B.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005037819-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS B.V. (NL) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | SPPL2A 1106/4885 |
| US-20150225414-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | SPPL2A 3123/4885 |
| US-20130289067-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | SERPINB1, HPN, DNPEP | SPPL2A 3123/4885 |
| US-20140148508-A1 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | CTRC, C9, CTSC | SPPL2A 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.